PARP1 and cardiac hypertrophy: This was confirmed by the intramyocardial injection of adenovirus-encoding PARP1, which augmented cardiac hypertrophy in vivo, whereas PARP inhibition with 3-aminobenzamide attenuated the detrimental effect of ADP-ribosylation.